Trial Profile

A PhaseI/II, Multicenter, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the Menin Inhibitor BN104 in the Treatment of Patients With Relapsed/Refractory Acute Leukemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BN 104 (Primary)
Indications Acute myeloid leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors BioNova Pharmaceuticals

10 Dec 2024 The Ph1 dose escalation part has completed, according to the results presented at the 66th American Society of Hematology Annual Meeting and Exposition.
10 Dec 2024 Results(As of data cutoff (30Jun2024, n= 20) of initial data from Phase (Ph) 1 dose escalation and dose optimization cohorts in patients (pts) with relapsed/refractory (R/R) AL, presented at the 66th American Society of Hematology Annual Meeting and Exposition
20 Feb 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com